|
safety |
16 |
|
major adverse cardiovascular events |
13 |
|
bnt162b2 |
11 |
|
cohort study |
11 |
|
coronavac |
11 |
|
covid-19 vaccine |
10 |
|
self-controlled case series |
10 |
|
adverse events of special interest (aesi) |
9 |
|
cancer |
9 |
|
covid-19 |
9 |
|
secondary prevention |
9 |
|
statins |
9 |
|
vaccine |
9 |
|
cardiovascular diseases |
8 |
|
drug utilization |
8 |
|
machine learning |
8 |
|
primary prevention |
8 |
|
recurrent cardiovascular events |
8 |
|
risk prediction score |
8 |
|
stroke |
8 |
|
adherence |
7 |
|
aspirin |
7 |
|
barriers |
7 |
|
colorectal cancer |
7 |
|
dementia |
7 |
|
focus group |
7 |
|
hypercholesterolemia |
7 |
|
lipid-lowering agents |
7 |
|
metformin |
7 |
|
preferences |
7 |
|
type 2 diabetes mellitus |
7 |
|
anticoagulant |
6 |
|
antiplatelet |
6 |
|
burden of disease |
6 |
|
elderly care |
6 |
|
epidemiology |
6 |
|
gastroenterology |
6 |
|
gastrointestinal tumours |
6 |
|
healthcare resource |
6 |
|
neuroleptic agent |
6 |
|
pneumonia admission |
6 |
|
population aging |
6 |
|
preventive medicine |
6 |
|
primary care |
6 |
|
proton pump inhibitors |
6 |
|
psychological symptoms |
6 |
|
self-controlled case series study |
6 |
|
global healthsales |
5 |
|
hong kong |
5 |
|
lipid-modifying agents |
5 |
|
low-density lipoprotein cholesterol |
5 |
|
myocardial infarction |
5 |
|
percutaneous coronary intervention |
5 |
|
pharmacoepidemiology |
5 |
|
transient ischaemic attack |
5 |
|
accident and emergency department attendances |
4 |
|
asians |
4 |
|
berberine |
4 |
|
blood glucose |
4 |
|
cardiovascular disease |
4 |
|
dosing |
4 |
|
dyslipidemia |
4 |
|
effectiveness |
4 |
|
efficacy |
4 |
|
hospital admissions |
4 |
|
initiation |
4 |
|
insulin resistance |
4 |
|
mortality |
4 |
|
prescribing |
4 |
|
sex-specific effect |
4 |
|
statin |
4 |
|
substance use disorders |
4 |
|
type 1 diabetes mellitus |
4 |
|
women |
4 |
|
adverse drug event |
3 |
|
antiplatelets |
3 |
|
anxiety |
3 |
|
atrial fibrillation |
3 |
|
cholesterol |
3 |
|
cohort studies |
3 |
|
depression |
3 |
|
direct oral anticoagulants |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors |
3 |
|
income level |
3 |
|
medication regimen complexity |
3 |
|
p2y12 inhibitors |
3 |
|
sales trends |
3 |
|
seizure |
3 |
|
suicide attempt |
3 |
|
warfarin |
3 |
|
antibiotic prescribing |
1 |
|
antibiotic use |
1 |
|
antimicrobial stewardship |
1 |
|
cardiovascular agents |
1 |
|
case mix |
1 |
|
covid-19 vaccination |
1 |
|
heterogeneity |
1 |
|
hospitalized patients |
1 |
|
inpatient prescribing |
1 |
|
statins (cardiovascular agents) |
1 |
|
sundowning |
1 |
|
treatment |
1 |
